Stealth Peptides Inc.
12 articles about Stealth Peptides Inc.
-
Stealth Peptides Inc. Release: Leading Cardiovascular Researchers Present Promising Bendavia Findings at 2013 European Society of Cardiology Heart Failure Congress
6/24/2013
-
Stealth Peptides Inc. Reports Successful Clinical Study of Oral Bendavia
1/22/2013
-
Stealth Peptides Inc. Initiates Patient Enrollment for Novel Treatment of Acute Kidney Injury
1/16/2013
-
Stealth Peptides Inc. Reports Results from Phase I Clinical Drug Interaction Studies with Bendavia
4/9/2012
-
Stealth Peptides Inc. Release: Dr. Robert Kloner Presents Bendavia Research at 2011 American Heart Association Annual Meeting
11/28/2011
-
Stealth Peptides Inc. Release: Researchers Present Promising Bendavia Findings at Annual Stealth Peptides Inc. Meeting
11/15/2011
-
Stealth Peptides Inc. Release: Bendavia Presented at 2011 American Heart Association’s Cardiovascular Scientific Sessions
8/1/2011
-
Stealth Peptides Inc. Announces Results from Renal Impairment Clinical Study
6/27/2011
-
Stealth Peptides Inc.' Bendavia(TM) Recognized as One of Stealth Peptides Inc.'s Top 10 Cardiovascular and Metabolic Development Programs to Watch
11/8/2010
-
Stealth Peptides Inc. Announces Clinical Phase I Results With Bendavia(TM) Demonstrating Safety And Tolerability With Highly Predictable Pharmacokinetics
9/13/2010
-
Stealth Peptides Inc. Completes Initial Phase I Clinical Trial Cohort with BendaviaTM, a Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury
6/14/2010
-
Stealth Peptides Inc. Announces FDA IND Approval for Conduct of Clinical Studies with Bendavia(TM), A Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury
5/17/2010